It looks as if Pfizer is going to have to submit to some counseling from a group of anxious economic development officials in Connecticut before the pharma giant will be allowed to reduce a sprawling R&D facility to rubble.
Pfizer CEO Ian Read has given yet another glimpse into the future of the drugmaker as he shapes it into a more efficient pharmaceutical operation. In a disappointing disclosure to those who look for more spinoffs, he said Pfizer will hold onto its consumer health business.
Drugs being pulled off of shelves because of bad odors generally have no health risks associated with them, but they cost drugmakers money and consumers inconvenience.
Pfizer's potential liability on off-label Neurontin use just grew: A U.S. appeals court in Boston upheld a $142 million verdict in one lawsuit and reinstated two others that had been tossed out by lower courts--including a class action that could allow hundreds of health plans to pursue claims against the company
A pilot study has brought dispiriting news for proponents of boosting vaccine adherence through text messaging. A study found that a series of text message prompts failed to increase vaccination rates among pregnant women.
The venture arms for Johnson & Johnson and Pfizer have helped spearhead an $18 million investment round for Canada's Aquinox Pharmaceuticals as the biotech plots the next big step in a mid-stage program for its lead anti-inflammatory drug.
Some Big Pharma heavyweights are duking it out for Brazil's Aché Laboratorios Farmaceuticos. Reuters sources say Pfizer, Novartis and Abbott Laboratories are in the fight, sizing up second-round bids in a deal worth around $5 billion.
Just a few months after inking a tie-up with Amgen, Bind Therapeutics has come back from the deal table with another marquee partner looking to use its nanoengineering platform to launch newly amped-up treatments into the clinic.
Now that Pfizer ( $PFE ) has wrapped up its big round of layoffs in Groton, CT, the company is bringing in the wrecking ball. And its plan to raze Building 118, Pfizer's sprawling...
Now that Pfizer has completed its big round of layoffs at Groton, CT, the pharma giant has decided to bring in the wrecking ball for Building 118, its sprawling 750,000-square-foot research facility on the campus.